Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Quite a lot of useful discussion about the delay to cv of the avacta branded test - ultimately nothing to worry about I think but definitely frustrating.
Less discussed are the reasons behind the delay to the sovereign test - we are leading its development with Mologic but it’s not managed by us. I don’t really buy the arguments about this being down to porton down incompetence. My experience with government contract delays is that this is almost always due to government clients moving the goalposts. I reckon that when it does appear (and the signed contracts with odx and gad would seem to suggest it is close) that it may surprise. Perhaps it will be a 2nd gen test combining S&N to achieve specificity plus sensitivity good to enough to open up travel. Or perhaps a test that can simultaneously detect multiple variants....
Unprecedented - things have evolved rapidly recently, pivoting in favour of self testing with the widely discredited Innova tests are being delivered in volume for home use. And yet AVCT is apparently at present are validating for professional use only. Something does not add up. Can you enlighten!
Fardistanhills...
You must have professional use acredited first before you can submit for self use.
OK thanks Raprap - I think I was aware of that (!) and so I ought to have given a bit of thought to it. But when I do think about it, it then begs the question is the £8bn DPS set up to procure for professional use, self testing or any mix of both? I think the answer is, its too late at night for my small size brain to be puzzling over such things!
Mologic and Avacta are working on something together, that's for sure. Avacta is at the centre alongside Mologic of the rapid test consortium, Avacta are reagent providers, so for Avacta not to involve their reagents in whatever capacity, it seems v unlikely. What else does the consortium need of Avacta? An S+N test with Avacta/Mologic being coy about its development, an N test using Affimer reagent and Mologic N protein breakdown tech or simply just the Avacta as is standalone test (I personally am leaning towards the 2nd). Either way good for Avacta. Anyone saying it doesn't matter if Avacta don't win a govt contract is trying to dampen expectations or trying to reassure their own concerns that Avacta will still do well without it. They might do ok in my mind but entering foreign markets is a lot easier with uk govt endorsement. The amount of misinformation in the lft market as is (sen/spec figures based on nasopharyngeal despite advertising nasal swab, which btw is in itself a confusing detail, usually means mid turbinate and can be easily conflated with anterior only) is pervasive, how is Avacta meant to separate itself without uk govt endorsement? Being the best S test isn't good enough imo.
Regarding MHRA self test accreditation, I'm sure this will come quickly if it is not already being assessed for self test by PHE. Sampling method is key here, a consistently sensitive anterior test should be all thats key given that Innova MHRA accreditation was essentially based on a test with a converted sampling method that should be easier to administer consistently at home. Professional accreditation should just be a formality. I wouldn't be surprised if govt forced through Innova self test just so they had a self test test to offer over the past weeks because their Liverpool self test results were far from good.
You mean(and I suspect) AS did not draw up a collaboration with Mologic specifying the S protein test as conditional before an S/N test which is supposedly, if he ever gets one out, to prove from data in use that it can control the pandemic. I don't mind a S/N test but would like AS to actually do something with affimers only or doesn't he really believe in them.
If he can't dot the Is and cross the Ts he will be walked all over and he needs a test for the S protein using affimer reagent mixture to prove his laboratory data. Maybe affimers can detect the N protein too together with some Mologic chemistry but we would be halving the reagent profit take and not showing what AVCT can do on its own.
He should nip out to Brazil and see if he can get something saliva based up and running quickly where there are plenty of infections.
Yep Affimers are ****e and Smith knows it, listen to just how bad they are in the ELISA test (5 mins onwards), you know the test ABCAM are now selling globally as the "best of its kind"
https://avacta.com/alastair-smith-gives-more-detail-on-the-sars-cov-2-elisa-laboratory-test/
Doze such a weird post suggests your posts are not ever worth reading and yet you've done so many. What a waste of data room space
So many posters seem to think it is so easy to do. They seem to forget the size of Avacta and the remarkable things they are trying to achieve. And will achieve.
Thanks Tim interesting on that video it was the ABCAM one he compared it to last September also on that slide confirmation that the ABCAM test was 500timres less sensitive.
No wonder they swapped to affimers
Agree with Unprecedented (as well as MD and others) that there’s likely more going on behind the scenes with the entire U.K. diagnostic industry collaboration, and that news when it comes may be an “out of left field” surprise.
This is just the CEO of Vatic talking about this collaborative exercise back on 17/2 (from 20 secs onwards)
https://twitter.com/TimesRadio/status/1362030713256759305
Our AN test is developed. Finished. Completed. Perfected. Ended. Concluded. It all over.
I’d have thought they’d have had a zoom party, PresAl would have worn his snazzy patterned shumper and there’d have been japes a plenty - he’ll have used the press briefing room as his virtual background.
Once the hangovers have gone, you’re left with a bunch of scientists kicking about twiddling their thumbs, probably on furlough... or they’ll have cracked straight on with the continued collaboration with Mologic on the S/N test. The joint working practices they’ll have established will have given them a running start so I’m sure development will be faster than the AN test. My best guess would be it’ll turn up as soon as possible during the summer, so in a few weeks.